Log In
BCIQ
Print this Print this
 

ALTU-238

  Manage Alerts
Collapse Summary General Information
Company Ajinomoto Co. Inc.
DescriptionSubcutaneous long-acting formulation of recombinant human growth hormone (rhGH)
Molecular Target Growth hormone receptor
Mechanism of ActionHormone replacement therapy
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationGrowth hormone deficiency
Indication DetailsTreat growth hormone deficiency (GHD) in adults; Treat growth hormone deficiency (GHD) in children
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/10/2010

Undisclosed

Undisclosed

0

Get a free BioCentury trial today